Chemical Engineering @ChemengFiles.Com

Kiadis Pharma has announced that Andrea Velardi, MD, professor of Clinical Immunology at the University of Perugia (Italy) and Kiadis Pharma will continue their collaboration on ATIR (TM), a product in clinical development to enable the use of a poorly matched donor in a bone marrow transplant preventing graft versus host disease (GvHD) for leukemia patients undergoing final. Under the agreement, Professor Velardi continue the development of selective reduction of T cells alorreactivas poorly matched donor using the proceeds of Kiadis Pharma, ATIR (TM). Kiadis Pharma is preparing for a pivotal multicenter study on ATIR (TM) to begin in early 2009 and Professor Velardi participate in this next survey.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, an eminence in the field of transplantation of bone marrow poorly matched," said doctorManja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR (TM) as a revolutionary approach to offer bone marrow transplants safer and ill-matched life-saving treatment option for patients with leukemia final stage."

Professor Andrea Velardidijo: "So far we have treated 25 patients with blood cancer who received a bone marrow donor poorly matched, including donor immune cells that are selectively reduce the cells that cause the disease of acute graft versus host using the process ATIR (TM). The results so far are promising and therefore I'm happy to continue working with Kiadis Pharma in this field. "